Gapping down
In reaction to disappointing earnings/guidance: NDLS -22.6%, CNAT -11.8%, VCYT -11.6%, TKMR -11.3%, (also - co remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola, expects matter to be resolved by Q4 2014; co also reported earnings), XONE -9.9%, YUME -9.1%,DGLY -8.7%, VJET -8.2%, OCLR -5.8%, VIPS -3.5%, DANG -3.5%, EXXI -3.3%, AEG -2.4%, CSCO -1.5%, SLW -1.2%, CIG -1.2%.
M&A news: NRG -1% (reaches agreement to acquire Goal Zero; financial terms not disclosed).
Select metals/mining stocks trading lower: RIO -2% ACH -1.9%, SLW -1.2%, CLF -0.9%, BHP -0.7%.
Other news: CNAT -11.8% (co said it is deferring the announcement of top-line results from the Phase 2 NAFLD/NASH clinical trial to Q1 2015; co also reported earnings), FSFR -8% (announced public offering of 22.8 mln shares of common stock), ENPH -5.6% (announced proposed public offering of common stock by selling stockholders), PDII -3.5% (co's subsidiary Interpace Diagnostics entered the molecular diagnostics market with thyroid and pancreatic cancer test portfolio acquisition of miRInform for $8 mln in upfront cash, future commercial milestone-based payments, and royalties), AMH -3.2% (announced public offering of 13 mln shares of Class A common shares), AMGN -2.2% (announced that the Phase 3 clinical trial FOCUS evaluating Kyprolis in patients with relapsed and advanced refractory multiple myeloma did not meet its primary endpoint), TKR -1.9% (announced proposed offering of $300 mln in senior notes due 2024).
Analyst comments: RMTI -4.2% (initiated with a Underperform at FBR Capital), ITMN -3% (downgraded to Neutral from Buy at Goldman), MSG -1.3% (downgraded to Hold at Topeka Capital Markets), SEAS -1.1% (downgraded to Market Perform from Outperform at Wells Fargo, downgraded to Neutral from Buy at BofA/Merrill), FCX -0.9% (downgraded to Hold from Buy at Stifel).
In reaction to disappointing earnings/guidance: NDLS -22.6%, CNAT -11.8%, VCYT -11.6%, TKMR -11.3%, (also - co remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola, expects matter to be resolved by Q4 2014; co also reported earnings), XONE -9.9%, YUME -9.1%,DGLY -8.7%, VJET -8.2%, OCLR -5.8%, VIPS -3.5%, DANG -3.5%, EXXI -3.3%, AEG -2.4%, CSCO -1.5%, SLW -1.2%, CIG -1.2%.
M&A news: NRG -1% (reaches agreement to acquire Goal Zero; financial terms not disclosed).
Select metals/mining stocks trading lower: RIO -2% ACH -1.9%, SLW -1.2%, CLF -0.9%, BHP -0.7%.
Other news: CNAT -11.8% (co said it is deferring the announcement of top-line results from the Phase 2 NAFLD/NASH clinical trial to Q1 2015; co also reported earnings), FSFR -8% (announced public offering of 22.8 mln shares of common stock), ENPH -5.6% (announced proposed public offering of common stock by selling stockholders), PDII -3.5% (co's subsidiary Interpace Diagnostics entered the molecular diagnostics market with thyroid and pancreatic cancer test portfolio acquisition of miRInform for $8 mln in upfront cash, future commercial milestone-based payments, and royalties), AMH -3.2% (announced public offering of 13 mln shares of Class A common shares), AMGN -2.2% (announced that the Phase 3 clinical trial FOCUS evaluating Kyprolis in patients with relapsed and advanced refractory multiple myeloma did not meet its primary endpoint), TKR -1.9% (announced proposed offering of $300 mln in senior notes due 2024).
Analyst comments: RMTI -4.2% (initiated with a Underperform at FBR Capital), ITMN -3% (downgraded to Neutral from Buy at Goldman), MSG -1.3% (downgraded to Hold at Topeka Capital Markets), SEAS -1.1% (downgraded to Market Perform from Outperform at Wells Fargo, downgraded to Neutral from Buy at BofA/Merrill), FCX -0.9% (downgraded to Hold from Buy at Stifel).